G-CSF Agonist Induction of Cardiomyocyte Differentiation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for inducing differentiation of ES cells into cardiomyocytes are inefficient and non-selective, resulting in low cardiomyocyte purity and yield, making them unsuitable for clinical applications such as heart failure treatment.

Innovation Solution

The use of G-CSF as an agonist for the G-CSF receptor, combined with the inhibition of BMP signaling using Noggin, during specific stages of ES cell culture to enhance cardiomyocyte differentiation and proliferation, leading to a higher selectivity and efficiency of cardiomyocyte production.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If conventional methods are used to induce differentiation of ES cells into cardiomyocytes, then cardiomyocytes can be obtained, but the purity and yield are low

Engineering Contradiction:

Improvecardiomyocyte purityVSAvoidcardiomyocyte yield

Core Design Contradiction:

Manufacturing precisionVSProductivity

Solution Approach 1:

The patent applies parameter changes by introducing G-CSF at specific concentrations (e.g., 10 ng/mL) during critical time windows (days 3-7 of EB formation) to optimize cardiomyocyte differentiation. This temporal and concentration-based parameter control enables selective induction of cardiomyocytes while suppressing other cell types, thereby improving both purity and yield simultaneously

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs preliminary action by pre-treating embryoid bodies with G-CSF during the early differentiation stage (days 3-7) before cardiomyocyte specification occurs. This early intervention establishes a favorable differentiation environment that directs ES cells toward the cardiomyocyte lineage, resulting in higher purity and yield of cardiomyocytes in the final population

Inventive Principle:

Principle #10Preliminary action

2Productivity

If G-CSF is added during specific culture stages, then cardiomyocyte differentiation efficiency increases, but the culture process complexity increases

Engineering Contradiction:

Improvecardiomyocyte differentiation efficiencyVSAvoidculture process complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent segments the differentiation process into distinct phases with specific G-CSF treatment windows. By dividing the culture period into stages (e.g., days 0-2 without G-CSF, days 3-7 with G-CSF, days 8-14 without G-CSF), the method achieves high differentiation efficiency while maintaining manageable procedural complexity through clear temporal boundaries

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method significantly increases the purity and yield of cardiomyocytes, making them suitable for potential use in myocardial regeneration and heart disease treatment by promoting efficient and selective differentiation of ES cells into cardiomyocytes.

Implementation Method 1

The use of G-CSF as an agonist for the G-CSF receptor

Methodology Applied

Scientific EffectReceptor agonism:

Implementation Method 2

the inhibition of BMP signaling using Noggin

Methodology Applied

Scientific EffectSignal transduction inhibition:

Data Source

PatentEP2154242B1Method of inducing differentiation into myocardial cells using g-csf

Publication Date: 2016.01.06 FUKUDA

Figure 1
Figure 2
Figure 3~4

AI summary

A method for inducing differentiation of ES cells into cardiomyocytes, which comprises contacting the ES cells with an agonist for G-CSF receptor.